Pelthos Therapeutics’ Post

Non-Alcoholic Steatohepatitis Pipeline Insights 2024: Therapies, Clinical Trials, and MOA, ROA by DelveInsight | Viking Therapeutics, Seal Rock Therapeutics, AstraZeneca, Boehringer Ingelheim, Oramed: (Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Non-Alcoholic Steatohepatitis pipeline constitutes 80+ key companies continuously working towards developing 80+ Non-Alcoholic Steatohepatitis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes … Continue reading → #Business #HealthMedicine #MarketingSales #PharmaceuticalsBiotech

MEMBER NEWS: ZyVersa Therapeutics Engages CRO, George Clinical, for Phase 2a Clinical Trial for Cholesterol Efflux Mediator VAR 200 -Cholesterol Efflux MediatorTM VAR 200 is in development to ameliorate renal lipid accumulation that damages the kidneys’ filtration system, leading to chronic kidney disease and its progression. WESTON, Fla., Dec. 14, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics Inc. Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with renal and inflammatory diseases who have unmet medical needs, announces selection of contract research organization (“CRO”) George Clinical to manage its Phase 2a clinical trial with Cholesterol Efflux MediatorTM VAR 200 in patients with diabetic kidney disease (DKD). The clinical trial is expected to begin in the first quarter of 2024. View full news release: https://lnkd.in/e9v_HMeu

AbbVie and Landos Biopharma, Inc. Biopharma ("Landos") today announced a definitive agreement under which AbbVie will acquire Landos, a clinical stage biopharmaceutical company focused on the development of novel, oral therapeutics for patients with autoimmune diseases. Landos' lead investigational asset is NX-13, a first-in-class, oral NLRX1 agonist (a member of the NOD-like receptor family) with a bimodal mechanism of action (MOA), which is anti-inflammatory and facilitates epithelial repair. "With this acquisition, we aim to advance the clinical development of NX-13, a differentiated, first-in-class, oral asset with the potential to make a difference in the lives of people living with ulcerative colitis and Crohn's disease," said Roopal Thakkar, M.D., senior vice president, chief medical officer, global therapeutics, AbbVie. "This announcement is a testament to Landos' talented team and their commitment to our mission of creating oral treatments that can address a therapeutic gap," said Gregory Oakes, president and chief executive officer, Landos. "NX-13 and its bimodal MOA have the potential to provide a novel approach to the treatment of ulcerative colitis and Crohn's disease. With AbbVie's therapeutic area leadership and expertise in global development, they are the right company to further advance NX-13." Under the terms of the agreement, AbbVie will acquire Landos at a price of $20.42 per share in cash upon closing, or approximately $137.5 million in the aggregate, plus one non-tradable contingent value right per share with a value of up to $11.14 per share, or approximately an additional $75 million in the aggregate, subject to the achievement of a clinical development milestone. The proposed transaction is expected to close in the second calendar quarter of 2024, subject to customary closing conditions, including approval by Landos' stockholders. #immunology #autoimmunediseases #ulcerativecolitis #crohnsdisease  #acquisition #Landos #AbbVie #AbbVieImmunology  👉 AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases - Mar 25, 2024

Hidradenitis Suppurativa Clinical Trials 2024: FDA Approvals, Pipeline, Medication, Therapies, Mechanism of Action, Route of Administration and Companies by DelveInsight: Hidradenitis Suppurativa Clinical Trials Hidradenitis Suppurativa companies are Kymera Therapeutics, Novartis, Incyte Corporation, Pfizer, Lytix Biopharma, Aclaris Therapeutics, AbbVie, Azora Therapeutics, InflaRx, UCB, ChemoCentryx, Amgen, Eli Lilly, Janssen Biotech, Boehringer Ingelheim, CSL Behring, and others. (Albany, United States) As per … Continue reading → #Business #HealthMedicine #MarketingSales #PharmaceuticalsBiotech

Deep Vein Thrombosis Market Statistics Expected to Experience Major Growth by 2032, According to DelveInsight | Bayer, LEO Pharma, Agen Biomedical, MinaPharm Pharma, GlaxoSmithKline, Pfizer: Key Deep Vein Thrombosis Companies in the market include – Bayer, LEO Pharma, Agen Biomedical, Bristol-Myers Squibb, Sanofi, Ottawa Hospital Research Institute, Daiichi Sankyo, MinaPharm Pharmaceuticals, GlaxoSmithKline, Pfizer, Anthos Therapeutics, Inc., and others.   DelveInsight’s “Deep Vein Thrombosis Market Insights, … Continue reading → #Business #HealthMedicine #MarketingSales #PharmaceuticalsBiotech

Myelofibrosis Pipeline Forecast 2024: FDA Approvals, Therapies, and Leading Companies by DelveInsight | Galecto Biotech, Lynk Pharma, Samus Therapeutics, Taiga Biotech, Bristol-Myers Squibb, Sumitomo: (Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Myelofibrosis pipeline constitutes 45+ key companies continuously working towards developing 45+ Myelofibrosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. The … Continue reading → #Business #HealthMedicine #MarketingSales #PharmaceuticalsBiotech

Learn how Calyx #MedicalImaging delivered critical imaging data in advance of deadlines on an expedited timeline to help a leading pharmaceutical company receive #Accelerated FDA approval for a #MultipleMyeloma treatment. https://lnkd.in/g9STMrPK #ChooseCalyx #ClinicalTrials #Oncology Jason Xu #MyelomaActionMonth

𝐀𝐛𝐛𝐕𝐢𝐞 𝐭𝐨 𝐀𝐜𝐪𝐮𝐢𝐫𝐞 𝐋𝐚𝐧𝐝𝐨𝐬 𝐁𝐢𝐨𝐩𝐡𝐚𝐫𝐦𝐚, 𝐄𝐱𝐩𝐚𝐧𝐝𝐢𝐧𝐠 𝐀𝐮𝐭𝐨𝐢𝐦𝐦𝐮𝐧𝐞 𝐃𝐢𝐬𝐞𝐚𝐬𝐞 𝐏𝐢𝐩𝐞𝐥𝐢𝐧𝐞 AbbVie (NYSE: ABBV) AbbVie and Landos Biopharma, Inc. (NASDAQ: LABP) Landos Biopharma, Inc. announced a definitive agreement where AbbVie will acquire Landos, a clinical-stage biopharmaceutical company focusing on novel oral therapeutics for autoimmune diseases. The acquisition aims to advance Landos' lead asset, NX-13, a first-in-class oral NLRX1 agonist, for ulcerative colitis and Crohn's disease. "Acquiring Landos allows us to advance NX-13, a promising oral asset with potential to impact patients with ulcerative colitis and Crohn's disease," said Dr. Roopal Thakkar Roopal Thakkar, Senior Vice President and Chief Medical Officer at AbbVie. Gregory Oakes Gregory Oakes, President and CEO of Landos, highlighted NX-13's potential and Landos' commitment to addressing therapeutic gaps. NX-13 targets NLRX1, regulating immunometabolism and inflammation, key mechanisms in inflammatory bowel disease (IBD) pathogenesis. The Phase 2 NEXUS trial is currently enrolling patients. Under the agreement, AbbVie will acquire Landos for $20.42 per share in cash upon closing, with additional contingent value rights subject to a clinical development milestone. The transaction is expected to close in the second quarter of 2024. #AutoimmuneDiseases #AutoimmuneDiseases #PharmaAcquisition #TherapeuticAdvancement #NEXUStrial #MedicalBreakthrough #Agreement

Idiopathic Pulmonary Fibrosis Pipeline Forecast 2024: FDA Approvals, Therapies, and Treatment Outlook | FibroGen, MediciNova, Pliant Therapeutics, Horizon Pharma, Reviva Pharma, Roche, Vicore Pharma: (Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Idiopathic Pulmonary Fibrosis pipeline constitutes 80+ key companies continuously working towards developing 100+ Idiopathic Pulmonary Fibrosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and … Continue reading → #Business #HealthMedicine #MarketingSales #PharmaceuticalsBiotech

Join the 6th Exosome-Based Therapeutic Development Summit (Sept 17-29, 2024) - https://lnkd.in/ga5z-F6T Join the 6th Exosome-Based Therapeutics Development Summit in Boston, MA, this September to delve into groundbreaking advancements, access exclusive clinical data, and forge pivotal partnerships to define the future of exosome drug development. Learn from 30+ renowned speakers from across the development timeline, sharing groundbreaking insights in exosome research including Takeda, Aegle Therapeutics, RION Health, EVerZom and many more. Spanning the complete development cycle of exosome therapeutics from discovery through IND filing, this summit uniquely integrates cutting-edge research with practical commercialization strategies. It stands as a key industry meeting that bridges the gap between science and business, propelling clinical advancements. Don't miss the chance to connect with over 150 of the industry’s leading experts in exosome therapeutics, gain invaluable insights, and place your work at the forefront of pharmaceutical innovation. To learn more, download the Event Guide here: https://lnkd.in/ga5z-F6T Will I see you at this summit in September? Let me know in comments below. #exosomes #extracellularvesicles #advancedtherapies Hanson Wade Group Erin Thomas